NEW YORK, NY / ACCESSWIRE / October 23, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
BioSpecifics Technologies Corp. (NASDAQ:BSTC)
Merger Announcement: October 19, 2020
Transaction Details: Under the terms of the deal, Endo will commence an all-cash tender offer for all outstanding shares of BioSpecifics common stock at a price of $88.50 per share.
To learn more about the BSTC investigation and your rights, go to:
BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Agreement Announcement: October 5, 2020
Transaction Details: Under the terms of the merger, BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos' outstanding shares. Eidos stockholders will have the right to receive in the transaction, at their election, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share in the transaction.
To learn more about the BBIO investigation and your rights, go to:
PNM Resources, Inc. (NYSE:PNM)
Merger Announcement: October 21, 2020
Transaction Details: Under the terms of the merger, PNM shareholders will receive $50.30 in cash for each share of PNM common stock held at closing.
To learn more about the PNM investigation and your rights, go to:
Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: